STAT+: Are analysts too quick to gloss over Lilly’s liver case?

STAT PlusNewsletterThe Readout Are analysts too quick to gloss over Lilly’s liver case? Cytokinetics’ Myqorzo’s trial results, Johnson & Johnson’s IBD therapy, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Elaine ChenMay 5, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning.

I was having a fine day yesterday until my colleague shared this game that tests how good (or how bad in my case) your color perception is.Advertisement The need-to-know this morning Vertex Pharma reported first-quarter earnings that generally matched consensus, although the company said it was shelving an early stage, mRNA-based therapy for cystic fibrosis due to poor tolerability. The drug, called VX-522, was being developed as part of a collaboration with Moderna. Pfizer and Alkermes also reported earnings.

Viridian Therapeutics announced positive top-line results from a Phase 3 study of its drug, called elegrobart, in patients with chronic thyroid eye disease. Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease Cytokinetics said its drug Myqorzo significantly improved heart failure symptoms and cardiovascular fitness in patients with non-obstructive hypertrophic cardiomyopathy, an inherited heart disorder. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech May 5, 2026 STAT Plus: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease Biotech May 5, 2026 STAT Plus: Johnson & Johnson advances IBD therapy, despite trial miss Advertisement The Readout May 4, 2026 UCB to acquire maker of antibody treatments for autoimmune diseases Exclusive May 4, 2026 STAT Plus: Biotech raises $42 million to run Huntington’s disease trial The Readout May 1, 2026 STAT Plus: Axsome wins FDA nod for Alzheimer’s agitation Subscriber Picks